Annals of internal medicine

Weekly and Biweekly Bofanglutide Compared to Semaglutide in Chinese Patients with Type 2 Diabetes

Updated

Abstract

Bofanglutide is a novel glucagon-like peptide-1 receptor agonist under development for type 2 diabetes mellitus (T2DM) and overweight and obesity.

  • Bofanglutide may help regulate blood sugar levels in individuals with T2DM.
  • This medication could assist in weight management for people with obesity.
  • It is associated with the potential for improved metabolic health in overweight individuals.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

No competing interests reported.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free